Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Microencapsulation for the gastric passage and controlled intestinal release of immunoglobulin Y

Posted by on in 2005
  • Font size: Larger Smaller
  • Hits: 1624
  • Print

 Kovacs-Nolan J, Mine Y.
J Immunol Methods. 2005 Jan;296(1-2):199-209. Epub 2004 Dec 16
Department of Food Science, University of Guelph, Guelph, Ontario, Canada N1G 2W1.


Avian immunoglobulin (Ig) Y is a promising alternative for the treatment and prevention of enteric infections, and has shown to be effective against a number of gastrointestinal pathogens, including Escherichia coli, Salmonella, and rotavirus. However, its application is limited by its sensitivity to human gastrointestinal conditions.

Here, we report on the enteric coating of IgY-containing granules with a pH-sensitive methacrylic acid copolymer. A 35% (w/w) polymer coating was found to protect IgY from gastric inactivation in vitro, maintaining greater than 95% activity after 6 h in simulated gastric fluid. The IgY was slowly released from the microencapsulated granules upon exposure to simulated intestinal fluid, and retained 80% activity after 8 h exposure to pancreatic enzymes.

In vivo, using pigs as a model of human digestion, the encapsulated IgY retained significantly more activity than non-encapsulated IgY, indicating that microencapsulation with a methacrylic acid copolymer may be an effective method of protecting IgY from gastrointestinal inactivation, enabling its use for oral passive immunotherapy.

Last modified on